siRNA 접합체 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

The future of the global siRNA conjugate market looks promising with opportunities in the gene therapy and drug delivery markets. The global siRNA conjugate market is expected to reach an estimated $3.8 billion by 2035 with a CAGR of 15% from 2026 to 2035. The major drivers for this market are the increasing demand for gene therapies, the rising focus on targeted drug delivery, and the growing investment in molecular research.

• Lucintel forecasts that, within the type category, antibody-siRNA conjugate is expected to witness the highest growth over the forecast period.
• Within the application category, gene therapy is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the siRNA Conjugate Market

The siRNA conjugate market is experiencing rapid growth driven by advancements in gene silencing technologies and targeted therapeutics. As researchers and pharmaceutical companies seek more precise and effective treatments for various diseases, innovative delivery methods and conjugate designs are emerging. These developments are transforming the landscape of genetic medicine, making therapies more accessible and personalized. The market is also influenced by regulatory approvals, technological breakthroughs, and increasing investments in biotech research. Understanding these trends is crucial for stakeholders aiming to capitalize on the evolving opportunities within this dynamic sector.

• Growing Focus on Targeted Delivery Systems: There is an increasing emphasis on developing conjugates that enhance delivery efficiency to specific cell types or tissues. This trend aims to improve therapeutic outcomes by minimizing off-target effects and reducing required dosages. Innovations include ligand-based conjugates, antibody conjugates, and nanoparticle carriers, which enable precise targeting. This focus is driven by the need for safer, more effective siRNA therapies, especially for complex diseases like cancer and genetic disorders. As a result, targeted delivery systems are becoming a key differentiator in the market, attracting significant R&D investments.
• Advances in Conjugate Design and Chemistry: Researchers are exploring novel chemical linkers and conjugation techniques to improve stability, bioavailability, and cellular uptake of siRNA molecules. These innovations help overcome biological barriers such as degradation by nucleases and poor cellular penetration. Enhanced conjugate designs also facilitate controlled release and reduced immunogenicity, leading to better therapeutic profiles. The development of biodegradable and biocompatible linkers is particularly impactful, enabling safer and more effective treatments. These advancements are expanding the scope of siRNA conjugates for various clinical applications.
• Increasing Regulatory Approvals and Clinical Trials: The market is witnessing a rise in clinical trials and regulatory clearances for siRNA conjugate-based therapies. This trend signifies growing confidence in the safety and efficacy of these treatments, encouraging further investment. Regulatory milestones, such as FDA approvals, are paving the way for commercialization and broader adoption. The ongoing trials are also providing valuable data on dosing, safety, and long-term effects, which are critical for market expansion. This trend is expected to accelerate the development pipeline and foster innovation within the industry.
• Rising Investments and Collaborations: Major pharmaceutical companies, biotech firms, and academic institutions are increasing their investments in siRNA conjugate research. Strategic collaborations are forming to leverage expertise in chemistry, delivery systems, and clinical development. Funding from venture capital and government grants is also fueling innovation. These investments are crucial for overcoming current challenges and accelerating product development. The collaborative approach fosters knowledge sharing and technological breakthroughs, ultimately leading to more effective and commercially viable siRNA conjugate therapies.
• Expansion into New Therapeutic Areas: The application of siRNA conjugates is broadening beyond traditional indications like genetic disorders to include cancer, infectious diseases, and inflammatory conditions. This diversification is driven by the ability of siRNA to silence disease-causing genes precisely. As research progresses, new conjugate formulations are being tailored for different disease environments, expanding market potential. This trend is opening up new revenue streams and increasing market competitiveness. The ability to address unmet medical needs with targeted gene silencing is positioning siRNA conjugates as versatile tools in personalized medicine.

In summary, these emerging trends are collectively reshaping the siRNA conjugate market by enhancing delivery precision, improving chemical stability, gaining regulatory confidence, attracting investments, and broadening therapeutic applications. These developments are driving innovation, increasing market adoption, and paving the way for more effective genetic therapies in the future.

Recent Developments in the siRNA Conjugate Market

The siRNA conjugate market is experiencing rapid growth driven by advancements in targeted gene silencing therapies. Innovations in conjugation techniques and delivery systems are expanding applications across various diseases, including cancer and genetic disorders. Increased research funding and regulatory approvals are further accelerating market expansion. As precision medicine gains prominence, the demand for efficient siRNA delivery methods is rising. These developments are transforming the landscape, offering new therapeutic options and improving patient outcomes, thereby creating significant opportunities for industry stakeholders.

• Growing Demand for Targeted Gene Therapy: The increasing prevalence of genetic disorders and cancers is driving demand for precise gene silencing solutions. siRNA conjugates enable targeted delivery, reducing off-target effects and enhancing treatment efficacy. This growth is supported by technological advancements and a better understanding of disease pathways, making siRNA conjugates a promising therapeutic approach. The market benefits from rising investments in personalized medicine, expanding the scope of siRNA applications, and fostering innovation in conjugate design.
• Advances in Conjugation Technologies: New conjugation methods, such as lipid, antibody, and ligand conjugates, are improving siRNA stability and delivery efficiency. These innovations enable better cellular uptake and reduced degradation, increasing therapeutic potential. Enhanced conjugation techniques also allow for customization based on disease targets, broadening application possibilities. As these technologies mature, they are expected to lower production costs and improve scalability, making siRNA conjugates more accessible and commercially viable.
• Increasing Regulatory Approvals and Clinical Trials: Regulatory agencies are approving more siRNA-based therapies, boosting market confidence and adoption. Numerous clinical trials are demonstrating safety and efficacy, encouraging further investment. These approvals facilitate commercialization and foster partnerships between biotech firms and pharmaceutical companies. The positive regulatory environment accelerates market growth, attracts funding, and encourages innovation, ultimately leading to more effective therapies reaching patients faster.
• Rising Investments and Collaborations: The market is witnessing increased funding from venture capitalists, pharmaceutical giants, and government agencies. Strategic collaborations are fostering innovation in conjugate design and delivery systems. These investments support research and development, clinical trials, and manufacturing scale-up. Such partnerships also facilitate knowledge sharing and technology transfer, accelerating product development. The influx of capital and collaboration is vital for overcoming current challenges and expanding the market's reach globally.
• Expansion into New Therapeutic Areas: The versatility of siRNA conjugates is enabling their application in diverse fields such as infectious diseases, autoimmune disorders, and rare genetic conditions. This expansion opens new revenue streams and broadens market potential. Tailored conjugates are being developed to target specific tissues and cell types, enhancing treatment precision. As research progresses, the market is poised for significant growth, driven by unmet medical needs and the pursuit of innovative, targeted therapies.

The overall impact of these developments is a rapidly expanding siRNA conjugate market characterized by increased innovation, regulatory support, and broader therapeutic applications. This growth is enhancing treatment options, improving patient outcomes, and attracting substantial investments, positioning the market for sustained long-term success.

Strategic Growth Opportunities in the siRNA Conjugate Market

The siRNA conjugate market is experiencing rapid expansion driven by advancements in gene silencing therapies and targeted delivery systems. Increasing demand for precision medicine and personalized treatments is fueling innovation in conjugate technologies. Growing applications across various therapeutic areas, including oncology and infectious diseases, are creating new growth avenues. Strategic collaborations, technological breakthroughs, and regulatory approvals are further accelerating market development, making it a promising landscape for stakeholders seeking to capitalize on cutting-edge genetic therapies.

• Enhanced Targeted Delivery for Improved Therapeutic Efficacy: Developing conjugates that precisely deliver siRNA to specific cells or tissues minimizes off-target effects and enhances treatment outcomes. Innovations in ligand and antibody conjugation improve cellular uptake and stability, expanding therapeutic applications. This targeted approach increases the efficiency of gene silencing, reduces side effects, and broadens the scope of siRNA-based treatments, making it a key growth driver in the market.
• Expansion into Oncology and Infectious Disease Treatments: The rising prevalence of cancer and infectious diseases has prompted the adoption of siRNA conjugates for targeted therapy. Conjugates enable specific gene silencing in tumor cells or infected tissues, improving treatment precision. Ongoing research and clinical trials are validating their efficacy, leading to increased investment and product development. This expansion into new therapeutic areas is expected to significantly boost market growth and diversify application portfolios.
• Technological Innovations in Conjugate Design and Delivery Platforms: Advances in nanotechnology, chemical conjugation, and delivery vectors are revolutionizing siRNA conjugate development. These innovations improve stability, bioavailability, and cellular penetration of siRNA molecules. Enhanced delivery platforms facilitate administration routes such as oral or inhalation, broadening patient accessibility. Continuous R&D efforts are expected to yield more efficient, scalable, and cost-effective conjugate solutions, fueling market expansion.
• Growing Adoption of Personalized Medicine and Precision Therapies: The shift towards personalized treatment strategies is increasing demand for tailored siRNA conjugates. Custom-designed conjugates target individual genetic profiles, improving therapeutic outcomes and reducing adverse effects. This trend encourages collaborations between biotech firms and healthcare providers, fostering innovation. As precision medicine gains momentum, the market for customized siRNA conjugates is poised for substantial growth, driven by the need for highly specific and effective therapies.
• Strategic Collaborations and Regulatory Approvals Accelerating Market Penetration: Partnerships between biotech companies, pharmaceutical firms, and research institutions facilitate technological advancements and clinical validation. Regulatory approvals for siRNA conjugate-based therapies are streamlining market entry, boosting investor confidence. These collaborations and approvals are critical for scaling manufacturing, reducing costs, and expanding global access. As regulatory pathways become clearer, market penetration is expected to accelerate, supporting sustained growth and innovation in the siRNA conjugate landscape.

The overall impact of these opportunities is set to transform the siRNA conjugate market into a highly innovative, diversified, and rapidly growing sector. Advancements in delivery technologies, expanding therapeutic applications, and strategic collaborations will drive market expansion, improve patient outcomes, and foster new investment opportunities. This dynamic environment promises significant growth potential for industry stakeholders and the future of genetic medicine.

siRNA Conjugate Market Driver and Challenges

The siRNA conjugate market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in nanotechnology and molecular biology have enabled more efficient delivery systems, boosting market potential. Economic factors such as increasing healthcare expenditure and rising prevalence of genetic disorders further propel demand. Regulatory frameworks around gene therapy and RNA-based treatments also impact market development, either facilitating or constraining innovation. Additionally, challenges related to manufacturing costs, safety concerns, and intellectual property rights influence market dynamics. Understanding these drivers and challenges is essential for stakeholders aiming to capitalize on emerging opportunities within this rapidly evolving sector.

The factors responsible for driving the siRNA conjugate market include:-

• Technological Advancements: The development of novel conjugation techniques and delivery systems has significantly improved the stability, specificity, and efficiency of siRNA therapies. Innovations such as lipid nanoparticles and targeted conjugates enable precise delivery to diseased cells, reducing off-target effects. These technological improvements have expanded the scope of siRNA applications, making treatments more viable and appealing to pharmaceutical companies. As research continues, further breakthroughs are expected, fostering market growth and encouraging investment in this field.
• Rising Prevalence of Genetic and Chronic Diseases: The increasing incidence of genetic disorders, cancers, and infectious diseases worldwide is a major driver. As traditional treatments often face limitations, siRNA conjugates offer targeted, personalized therapeutic options. The growing patient population and the demand for innovative treatments are prompting healthcare providers and pharmaceutical companies to invest heavily in siRNA-based solutions, thereby expanding the market.
• Increasing Investment in R&D: Governments, private investors, and pharmaceutical companies are channeling substantial funds into research and development of siRNA conjugates. This financial support accelerates the discovery of new conjugation methods, enhances safety profiles, and streamlines manufacturing processes. The focus on clinical trials and regulatory approvals further boosts confidence in the market, leading to a broader pipeline of siRNA therapies entering the market.
• Regulatory Support and Approvals: Evolving regulatory frameworks that recognize the therapeutic potential of RNA-based treatments are facilitating market growth. Clear guidelines and accelerated approval pathways for gene therapies encourage companies to innovate and bring products to market more efficiently. Regulatory acceptance reduces uncertainties, attracts investments, and accelerates commercialization, thereby positively impacting the market landscape.
• Growing Adoption of Personalized Medicine: The shift towards personalized treatment approaches is a significant driver. siRNA conjugates enable targeted therapy tailored to individual genetic profiles, improving efficacy and reducing side effects. This trend aligns with the broader movement in healthcare towards precision medicine, encouraging pharmaceutical development and increasing market demand for customized siRNA solutions.

The challenges facing the siRNA conjugate market include:-

• Manufacturing and Cost Challenges: Producing siRNA conjugates involves complex, costly processes that require advanced technology and strict quality control. High manufacturing costs limit accessibility and affordability, especially in emerging markets. Additionally, scaling up production while maintaining consistency and safety remains a significant hurdle, potentially delaying product launches and increasing prices.
• Safety and Off-Target Effects: Despite technological improvements, concerns about unintended gene silencing and immune responses persist. These safety issues pose risks to patient health and hinder regulatory approval processes. Addressing these challenges requires extensive research and validation, which can be time-consuming and expensive, impacting market growth.
• Regulatory Uncertainties: Although regulatory frameworks are evolving, uncertainties remain regarding approval pathways, safety standards, and long-term effects of siRNA therapies. These ambiguities can delay product development, increase costs, and deter investment. Navigating diverse regulatory landscapes across regions adds complexity, potentially limiting market expansion.

In summary, the siRNA conjugate market is driven by technological innovations, increasing disease prevalence, and supportive regulatory environments, which collectively foster growth. However, manufacturing costs, safety concerns, and regulatory uncertainties pose significant challenges that could impede progress. The interplay of these factors will shape the market's evolution, requiring stakeholders to innovate and adapt strategically. Overall, the market holds substantial promise, but overcoming these hurdles is essential for realizing its full potential and delivering targeted, effective therapies to patients worldwide.

List of siRNA Conjugate Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies siRNA conjugate companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the siRNA conjugate companies profiled in this report include-

• WuXi XDC
• Creative Biogene
• Bachem
• LGC Biosearch Technologies
• Sinopep
• Organix
• CD Formulation
• Hitgen
• Alnylam Pharmaceuticals
• Amerigo Scientific

siRNA Conjugate Market by Segment

The study includes a forecast for the global siRNA conjugate market by type, application, and region.

siRNA Conjugate Market by Type [Value from 2019 to 2035]:

• Antibody-siRNA Conjugates
• GalNAc-siRNA Conjugates
• Peptide-siRNA Conjugates
• Others

siRNA Conjugate Market by Application [Value from 2019 to 2035]:

• Gene Therapy
• Drug Delivery
• Others

siRNA Conjugate Market by Region [Value from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the siRNA Conjugate Market

The siRNA conjugate market has experienced significant growth driven by advancements in gene therapy, targeted drug delivery, and personalized medicine. As research progresses, key players are innovating to improve efficacy, reduce side effects, and expand applications across various therapeutic areas. Regulatory approvals and increasing investments are further propelling market expansion in major economies. The evolving landscape reflects a focus on precision medicine, with countries adopting new technologies to address unmet medical needs. This dynamic environment underscores the importance of regional developments that influence global trends in siRNA conjugate research and commercialization.

• United States: The United States leads in siRNA conjugate market development, with substantial investments from biotech firms and government agencies. Recent approvals of siRNA-based therapies have accelerated market growth, supported by advancements in delivery systems like lipid nanoparticles. Research institutions are pioneering novel conjugates targeting cancer, genetic disorders, and infectious diseases. The U.S. regulatory framework facilitates rapid clinical translation, fostering innovation. Additionally, collaborations between academia and industry are driving new formulations and delivery mechanisms, positioning the country as a global leader in siRNA therapeutics.
• China: China has rapidly expanded its siRNA conjugate research, backed by government initiatives and increased funding for biotech innovation. Domestic companies are focusing on developing cost-effective, scalable delivery platforms to compete globally. Recent breakthroughs include novel conjugates targeting liver diseases and cancers, with several candidates entering clinical trials. The Chinese government's strategic plans aim to establish the country as a major hub for gene therapy development. Collaborations with international firms are also increasing, facilitating technology transfer and regulatory harmonization, which accelerates market entry and commercialization.
• Germany: Germany remains at the forefront of European siRNA conjugate research, emphasizing precision medicine and innovative delivery technologies. Leading biotech firms and research centers are developing conjugates with enhanced stability and targeted delivery capabilities. Recent advancements include conjugates for neurodegenerative diseases and rare genetic disorders. Germany's strong regulatory environment and focus on clinical validation support the translation of research into approved therapies. The country also benefits from robust funding programs and collaborations within the European Union, fostering a conducive environment for innovation and commercialization in the siRNA space.
• India: India's siRNA conjugate market is emerging, driven by increasing investments in biotech startups and research institutions. Focus areas include affordable therapies for infectious diseases and genetic disorders prevalent in the region. Recent developments involve novel delivery systems tailored for local healthcare needs, with some candidates progressing to clinical trials. Government initiatives aimed at promoting biotechnology innovation and manufacturing are supporting market growth. Additionally, collaborations with international companies are helping Indian firms adopt advanced technologies, positioning India as a potential hub for cost-effective siRNA therapeutics in the future.
• Japan: Japan is advancing in siRNA conjugate research through strong academic-industry collaborations and government support. The focus is on developing targeted therapies for cancer and age-related diseases, with recent innovations in conjugate stability and delivery efficiency. Several clinical trials are underway for siRNA-based treatments, reflecting Japan's commitment to precision medicine. The country's regulatory environment encourages innovation, and local companies are investing in next-generation conjugates. Japan's strategic emphasis on aging populations and chronic disease management further drives the development of siRNA therapeutics, positioning it as a key player in the global market.

Features of the Global siRNA Conjugate Market

• Market Size Estimates: siRNA conjugate market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
• Segmentation Analysis: siRNA conjugate market size by type, application, and region in terms of value ($B).
• Regional Analysis: siRNA conjugate market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the siRNA conjugate market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the siRNA conjugate market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the siRNA conjugate market by type (antibody-siRNA conjugates, GalNAc-siRNA conjugates, peptide-siRNA conjugates, and others), application (gene therapy, drug delivery, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global siRNA Conjugate Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Antibody-siRNA Conjugates : Trends and Forecast (2019-2035)
• 4.4 GalNAc-siRNA Conjugates : Trends and Forecast (2019-2035)
• 4.5 Peptide-siRNA Conjugates : Trends and Forecast (2019-2035)
• 4.6 Others : Trends and Forecast (2019-2035)

5. Global siRNA Conjugate Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Gene Therapy : Trends and Forecast (2019-2035)
• 5.4 Drug Delivery : Trends and Forecast (2019-2035)
• 5.5 Others : Trends and Forecast (2019-2035)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global siRNA Conjugate Market by Region

7. North American siRNA Conjugate Market

• 7.1 Overview
• 7.2 North American siRNA Conjugate Market by Type
• 7.3 North American siRNA Conjugate Market by Application
• 7.4 The United States siRNA Conjugate Market
• 7.5 Canadian siRNA Conjugate Market
• 7.6 Mexican siRNA Conjugate Market

8. European siRNA Conjugate Market

• 8.1 Overview
• 8.2 European siRNA Conjugate Market by Type
• 8.3 European siRNA Conjugate Market by Application
• 8.4 German siRNA Conjugate Market
• 8.5 French siRNA Conjugate Market
• 8.6 Italian siRNA Conjugate Market
• 8.7 Spanish siRNA Conjugate Market
• 8.8 The United Kingdom siRNA Conjugate Market

9. APAC siRNA Conjugate Market

• 9.1 Overview
• 9.2 APAC siRNA Conjugate Market by Type
• 9.3 APAC siRNA Conjugate Market by Application
• 9.4 Chinese siRNA Conjugate Market
• 9.5 Indian siRNA Conjugate Market
• 9.6 Japanese siRNA Conjugate Market
• 9.7 South Korean siRNA Conjugate Market
• 9.8 Indonesian siRNA Conjugate Market

10. ROW siRNA Conjugate Market

• 10.1 Overview
• 10.2 ROW siRNA Conjugate Market by Type
• 10.3 ROW siRNA Conjugate Market by Application
• 10.4 Middle Eastern siRNA Conjugate Market
• 10.5 South American siRNA Conjugate Market
• 10.6 African siRNA Conjugate Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global siRNA Conjugate Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 WuXi XDC
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Creative Biogene
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Bachem
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 LGC Biosearch Technologies
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Sinopep
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Organix
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 CD Formulation
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Hitgen
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Alnylam Pharmaceuticals
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Amerigo Scientific
  • Company Overview
  • siRNA Conjugate Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us